Atomoxetine in patients with recurrent vasovagal syncope for preventing vasovagal attacks and improvement of depression and anxiety: a randomized double-blind placebo-controlled clinical trial
Tajdini M, Aminorroaya A, Tavolinejad H, Tofighi S, Jalali A, Sadeghian S, Akhondzadeh S, Vasheghani-Farahani A, Yadangi S, Shahmansouri N, Bozorgi A. Atomoxetine in patients with recurrent vasovagal syncope for preventing vasovagal attacks and improvement of depression and anxiety: a randomized double-blind placebo-controlled clinical trial. European Heart Journal 2020, 41: ehaa946.0713. DOI: 10.1093/ehjci/ehaa946.0713.Peer-Reviewed Original ResearchPre-syncopal episodesImprove anxietyRecurrent vasovagal syncopeVasovagal syncopeEffects of atomoxetineSyncopal episodesImprovement of depressionPrimary endpointSignificant between-subjects effectAbstract Background StudiesHospital Anxiety and Depression ScaleAnxiety and Depression ScaleDouble-blind placebo-controlled randomized clinical trialPlacebo-controlled randomized clinical trialBetween-subject effectsPreventing recurrence of syncopeMonths of follow-upAtomoxetineCompared to placeboDepression scoresRecurrence of syncopeAnxietyDepressionDepression ScaleMann-Whitney U test